Fulgent GeneticsFLGT +5.17%59 FCF Margin % is 2.66% as of Mar. 2026, which is 6% above its 10-year median of 2.52. GuruFocus rates FLGT with a GF Score™ of 59/100 and a GF Value™ of $23.98 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Fulgent Genetics ranks worse than 74.02% on this metric.
The historical rank and industry rank for Fulgent Genetics's FCF Margin % or its related term are showing as below:
FLGT'
s FCF Margin % Range Over the Past 10 Years
Min: -38.49 Med: 2.52 Max: 51.86
Current: -35.33
During the past 12 years, the highest FCF Margin % of Fulgent Genetics was 51.86%. The lowest was -38.49%. And the median was 2.52%.
FLGT's FCF Margin % is ranked worse than 74.02% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.845
vs FLGT: -35.33
Fulgent Genetics FCF Margin % Related Terms
Fulgent Genetics FCF Margin % Historical Data
* Premium members only.
The historical data trend for Fulgent Genetics's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Fulgent Genetics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fulgent Genetics FCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Fulgent Genetics's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Fulgent Genetics's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fulgent Genetics (FLGT) has a FCF Margin % of 2.66% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Fulgent Genetics and its competitors. This is near median its historical median of 2.52. According to the industry distribution chart, Fulgent Genetics ranks #151 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 74%.
Is Fulgent Genetics' FCF Margin % too high?
Fulgent Genetics' current FCF Margin % of 2.66% is near median its 10-year median of 2.52. Based on the distribution chart, Fulgent Genetics ranks #151 out of 204 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Fulgent Genetics has a GF Score™ of 59/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fulgent Genetics' FCF Margin % compare to CSTL and MYGN?
According to the Medical Diagnostics & Research industry distribution chart, Fulgent Genetics ranks #151 out of 204 companies for FCF Margin %. This places Fulgent Genetics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Diagnostics & Research company?
A good FCF Margin % depends on the Medical Diagnostics & Research industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Fulgent Genetics and its competitors. Fulgent Genetics's current FCF Margin % is 2.66%, which is near median its own 10-year median of 2.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fulgent Genetics stock overvalued right now?
Based on GuruFocus' analysis, Fulgent Genetics (FLGT) is currently considered Modestly Undervalued. The stock's GF Value™ is $23.98, compared to a current price of $19.13 — trading 20.2% below its estimated fair value. The current FCF Margin % is 2.66%, which is near median its 10-year median of 2.52. Fulgent Genetics' overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Fulgent Genetics (FLGT), the current FCF Margin % is 2.66% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fulgent Genetics (FLGT) Overvalued in 2026?
Based on GuruFocus' analysis, Fulgent Genetics stock appears to be undervalued.
The current stock price of $19.13 is trading 20.2% below its estimated GF Value™ of $23.98.
GuruFocus considers Fulgent Genetics to be Modestly Undervalued.
Key valuation signals for FLGT:
FCF Margin %: 2.66% (near median its 10-year median of 2.52)
GF Value™: $23.98 vs. price of $19.13 (20.2% below fair value)
No single metric tells the full story. See the FLGT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.
59GF Score
Get the complete analysis for FLGT
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FLGT has been successfully added to your 
